These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34030557)

  • 1. Epoprostenol for the treatment of pulmonary arterial hypertension.
    Cristo Ropero MJ; Cruz-Utrilla A; Escribano-Subias MP
    Expert Rev Clin Pharmacol; 2021 Aug; 14(8):1005-1013. PubMed ID: 34030557
    [No Abstract]   [Full Text] [Related]  

  • 2. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.
    Simonneau G; Rubin LJ; Galiè N; Barst RJ; Fleming TR; Frost AE; Engel PJ; Kramer MR; Burgess G; Collings L; Cossons N; Sitbon O; Badesch DB;
    Ann Intern Med; 2008 Oct; 149(8):521-30. PubMed ID: 18936500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension.
    McLaughlin VV; Palevsky HI
    Clin Chest Med; 2013 Dec; 34(4):825-40. PubMed ID: 24267307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry.
    Bergot E; Sitbon O; Cottin V; Prévot G; Canuet M; Bourdin A; de Groote P; Rottat L; Gressin V; Jaïs X; Humbert M; Simonneau G
    Int J Cardiol; 2014 Apr; 172(3):561-7. PubMed ID: 24529947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary Edema Following Initiation of Parenteral Prostacyclin Therapy for Pulmonary Arterial Hypertension: A Retrospective Study.
    Khan NA; Khan RA; Tonelli AR; Highland KB; Chaisson NF; Jacob M; Renapurkar R; Dweik RA; Heresi GA
    Chest; 2019 Jul; 156(1):45-52. PubMed ID: 30776364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability, safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol (Veletri
    Degering J; Egenlauf B; Harutyunova S; Benjamin N; Salkić A; Xanthouli P; Eichstaedt CA; Seeger R; Sitbon O; Grünig E
    Respir Res; 2023 Jan; 24(1):18. PubMed ID: 36653855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epoprostenol Therapy for Pulmonary Arterial Hypertension.
    Akagi S; Nakamura K; Matsubara H; Ogawa A; Sarashina T; Ejiri K; Ito H
    Acta Med Okayama; 2015; 69(3):129-36. PubMed ID: 26101188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transition from intravenous epoprostenol to oral or subcutaneous therapy in pulmonary arterial hypertension: a retrospective case series and systematic review.
    Park K; Ostrow D; Levy RD; Swiston J
    Can Respir J; 2011; 18(3):157-62. PubMed ID: 21766080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.
    Kemp K; Savale L; O'Callaghan DS; Jaïs X; Montani D; Humbert M; Simonneau G; Sitbon O
    J Heart Lung Transplant; 2012 Feb; 31(2):150-8. PubMed ID: 22138355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid Dysfunction in Patients with Pulmonary Artery Hypertension (PAH): The Effect of Therapies Affecting the Prostanoid Pathway.
    Menon AA; Sahay S; Braverman LE; Farber HW
    Lung; 2019 Dec; 197(6):761-768. PubMed ID: 31696306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension.
    Petrovič M; Locatelli I
    Ann Pharmacother; 2020 May; 54(5):423-433. PubMed ID: 31735058
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination Therapy in Pulmonary Arterial Hypertension-Targeting the Nitric Oxide and Prostacyclin Pathways.
    Mandras S; Kovacs G; Olschewski H; Broderick M; Nelsen A; Shen E; Champion H
    J Cardiovasc Pharmacol Ther; 2021 Sep; 26(5):453-462. PubMed ID: 33836637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epoprostenol sodium for treatment of pulmonary arterial hypertension.
    Saito Y; Nakamura K; Akagi S; Sarashina T; Ejiri K; Miura A; Ogawa A; Matsubara H; Ito H
    Vasc Health Risk Manag; 2015; 11():265-70. PubMed ID: 25999730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid Titration of Intravenous Treprostinil to Treat Severe Pulmonary Arterial Hypertension Postpartum: A Retrospective Observational Case Series Study.
    Wang T; Lu J; Li Q; Chen Y; Ye Q; Gao J; Yang D; Zhao L; Huang J; Zhang J
    Anesth Analg; 2019 Dec; 129(6):1607-1612. PubMed ID: 31743181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid initiation of intravenous epoprostenol infusion is the favored option in patients with advanced pulmonary arterial hypertension.
    Kimura M; Tamura Y; Takei M; Yamamoto T; Ono T; Kuwana M; Fukuda K; Satoh T
    PLoS One; 2015; 10(4):e0121894. PubMed ID: 25844932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine.
    Douwes JM; Zijlstra WMH; Rosenzweig EB; Ploegstra MJ; Krishnan US; Haarman MG; Roofthooft MTR; Postmus D; Hillege HL; Ivy DD; Berger RMF
    Ann Am Thorac Soc; 2022 Feb; 19(2):227-237. PubMed ID: 34181866
    [No Abstract]   [Full Text] [Related]  

  • 17. Oral treprostinil in the treatment of pulmonary arterial hypertension.
    Feldman J; Habib N; Radosevich J; Dutt M
    Expert Opin Pharmacother; 2017 Oct; 18(15):1661-1667. PubMed ID: 28922964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Midterm postoperative prognosis of patients with severe left heart valvular disease combined with moderate or severe pulmonary hypertension treated with treprostinil.
    Xu N; Huang ST; Sun KP; Wang ZC; Cao H; Chen Q
    BMC Cardiovasc Disord; 2020 Nov; 20(1):472. PubMed ID: 33143649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
    Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
    J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effect of Perioperative Administration of Treprostinil in Infants with Non-restrictive Ventricular Septal Defect and Severe Pulmonary Arterial Hypertension.
    Huang ST; Xu N; Sun KP; Chen LW; Cao H; Chen Q
    Pediatr Cardiol; 2020 Oct; 41(7):1334-1339. PubMed ID: 32468125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.